Please login to the form below

Not currently logged in


This page shows the latest Iressa news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Tagrisso's first line approval, EULAR and EHA, and why Stephen Hawking was wrong on NHS

head-to-head with existing EGFR drugs, Roche’s Tarceva and AstraZeneca’s own Iressa.

Latest news

More from news
Approximately 6 fully matching, plus 71 partially matching documents found.

Latest Intelligence

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    It is a particularly pressing matter for AZ considering the company has several personalised medicines on market or in development, including Iressa (gefitinib) to treat lung cancer patients with a mutation

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    If approved, the drug would complement AZ's other NSCLC drug, Iressa, which is approved in NSCLC patients with the EGFR mutation. “ ... Another development is AZD9291 – a drug which addresses the T790M mutation, which is a key resistance mechanism to

  • Payer focus in the personalised world of oncology and orphan diseases Payer focus in the personalised world of oncology and orphan diseases

    more effective (eg Herceptin in HER2+ breast cancer, Iressa and Tarceva in EGFR mutation+ non-small cell lung cancer and Glivec in Philadelphia chromosome+ CML).

  • Market access opportunities in China Market access opportunities in China

    In part as a result of these efforts, both Tarceva and Iressa have been appraised in the Guideline for Diagnosis and Treatment of Primary Lung Cancer published by the Ministry of

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....